Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
Status:
Terminated
Trial end date:
2017-12-22
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if ibrutinib can help to control
lymphoma in patients who have had an autologous stem cell transplant (a transplant using your
own stem cells). The safety of this drug will also be studied.